Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy; a Placebo-controlled Trial

Launched by CHINESE UNIVERSITY OF HONG KONG · Jun 29, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at whether people who regularly take aspirin to protect their heart should continue or stop taking it when they have a colonoscopy, which is a procedure to check for colon cancer and remove any growths called polyps. Aspirin helps prevent heart attacks and strokes, but it can also increase the chance of bleeding after removing polyps during a colonoscopy. Right now, doctors don’t fully agree on the best approach because there hasn’t been a large, careful study comparing the two options. This trial will help find out which choice is safer for patients—continuing aspirin or stopping it before the procedure.

The study is for adults aged 65 to 74 who are taking aspirin daily (at least 80 mg) to prevent heart problems and who need a colonoscopy to screen for colon cancer. People who recently had a heart stent, a recent heart event, or who take other blood thinners won’t be eligible. If you take part, you will be randomly assigned to either keep taking aspirin or switch to a placebo (a pill that doesn’t contain aspirin) before your colonoscopy. The researchers will then watch for any heart problems or bleeding after the procedure. Your participation will help doctors make better recommendations for patients like you in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients receiving aspirin (80mg daily or more) for secondary prevention against cardiovascular diseases who require elective colonoscopy for colorectal cancer screening.
• Exclusion Criteria:
• • patients who received a coronary stent of any type within 6 months
• • patients who had a cardiovascular event within 3 months
• • patients who had concurrent use of anticoagulants (warfarin or NOAC) or other antiplatelet drugs (P2Y12 receptor antagonists)
• • patient with bleeding diathesis e.g., hemophilia, von Willebrand's disease or coagulopathy from liver cirrhosis
• • patient with terminal malignancies or medical illnesses.
• • patient who is unable or refuse to give consents